TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: guidance
This guidance has been partially updated by ‘Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C’ (NICE technology appraisal guidance 200).
This guidance is a review and extension of Technology Appraisal Guidance No. 14 issued in October 2000. The Institute reviews each piece of guidance it issues.
The review and re-appraisal has resulted in an extension to the guidance; combination therapy with pegylated interferon alfa and ribavirin is recommended for the treatment of people aged 18 years and over with moderate to severe chronic hepatitis C.
|
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: guidance
05 December 2005 (197.1 Kb 57 sec) |
This page was last updated: 31 May 2012